There is one summary for H.R.5235. Bill summaries are authored by CRS.

Shown Here:
Introduced in House (09/20/2000)

Prescription Drug Competition Act of 2000 - Requires a brand name drug company and a generic drug applicant that enter into an agreement regarding the sale or manufacture of a generic drug determined or likely to be the therapeutic equivalent of such brand name drug, when such agreement could limit the research, development, manufacture, marketing, or sale of such generic drug, to file with the Federal Trade Commission and the Secretary of Health and Human Services the text of such agreement and an explanation of whether such agreement could delay, restrain, limit, or otherwise interfere with the production, manufacture, or sale of the generic drug in question. Requires such filing within ten days of agreement execution. Provides civil penalties for violation.